A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

December 16, 2024

Study Completion Date

December 1, 2026

Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma
Interventions
DRUG

Tolinapant

Capsule for oral administration

DRUG

Decitabine + Cedazuridine

Tablet for oral administration

Trial Locations (46)

2139

Concord Hospital, Concord

3168

Monash Medical Center, Melbourne

6009

Linear Clinical Research Site #834, Nedlands

8025

Hospital de la Santa Creu i Sant Pau, Barcelona

8908

Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona

10016

NYU Langone Laura and Isaac Perlmutter Cancer Center Site #153, New York

13009

Institut Paoli-Calmettes, Marseille

14450

Rochester Skin Lymphoma Medical Group, PLLC Site #147, Fairport

19104

University of Pennsylvania Site# 160, Philadelphia

20141

Istituto Europeo di Oncologia Site#652, Milan

20900

Fondazione IRCCS San Gerardo dei Tintori Site #655, Monza

21287

Johns Hopkins University, Baltimore

22908

University of Virginia Comprehensive Cancer Center, Charlottesville

25123

Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia Site#650, Brescia

28040

Hospital Universitario Fundación Jiménez Díaz Site #703, Madrid

28041

Hospital Universitario 12 de Octubre Site#710, Madrid

30322

Winship Cancer Institute of Emory University, Atlanta

33000

Institut Bergonié Site#553, Bordeaux

33612

Moffitt Cancer Center Site #157, Tampa

34295

CHU Saint-Eloi Site#556, Montpellier

37000

Hôpital Bretonneau, Tours

39008

Hospital Universitario Marqués de Valdecilla Site#711, Santander

40138

U.O.C. di Ematologia Pad. 8IRCCS Azienda OspedalieroUniversitaria di Bologna Site#651, Bologna

41013

Hospital Universitario Virgen del Rocío, Seville

47014

"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST", Meldola

48109

University of Michigan Rogel Cancer Center, Ann Arbor

48121

Ospedale Santa Maria delle Croci di Ravenna, Ravenna

48201

Barbara Ann Karmanos Cancer Institute Site#159, Detroit

75013

AP-HP Pitie Saltpetriere Site# 552, Paris

76038

Centre Henri Becquerel, Rouen

77030

The University of Texas MD Anderson Cancer Center Site #101, Houston

80045

University of Colorado Anschutz Medical Campus Site #118, Aurora

90095

University of Califonia, Los Angeles, Los Angeles

91010

City of Hope Site #151, Duarte

94305

Stanford University, Stanford

94805

Institut Gustave Roussy, Villejuif

98109

Fred Hutchinson Cancer Center, Seattle

06511

Yale Cancer Center Site #109, New Haven

06189

Centre Antoine Lacassagne, Nice

02-781

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warsaw

80-214

Ośrodek Badań Klinicznych Wczesnych Faz - Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdansk

93-513

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi, Lodz

08003

Hospital del Mar Site #704, Barcelona

SE1 9Rt

Guy's and Saint Thomas' NHS Foundation Trust, London

W1T 7HA

University College London Hospitals NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY